title: Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia.
authors.forename: M
authors.initials: M
authors.lastname: Bocchia
authors.forename: E
authors.initials: E
authors.lastname: Abruzzese
authors.forename: F
authors.initials: F
authors.lastname: Forconi
authors.forename: M
authors.initials: M
authors.lastname: Ippoliti
authors.forename: M M
authors.initials: MM
authors.lastname: Trawinska
authors.forename: M T
authors.initials: MT
authors.lastname: Pirrotta
authors.forename: D
authors.initials: D
authors.lastname: Raspadori
authors.forename: M
authors.initials: M
authors.lastname: Tozzi
authors.forename: A
authors.initials: A
authors.lastname: Gozzetti
authors.forename: F
authors.initials: F
authors.lastname: Lauria
mesh_terms: D000293:Adolescent; D000328:Adult; D001549:Benzamides; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002648:Child; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D000068877:Imatinib Mesylate; D007111:Immunity, Cellular / Q000187:drug effects*; D007114:Immunization; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
chemical_list: D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate